Kiora Pharmaceuticals, Inc. (KPRX) News
Track canonical SquawkNews coverage tagged to KPRX, Kiora Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Kiora appoints Keith Lane as executive vice president
Kiora named Keith Lane executive vice president and head of clinical development and regulatory affairs, effective September 8, 2026.
REGULATION | Sep 08, 2026, 11:13 AM UTC
H
Kiora Pharmaceuticals signs exclusive CKD license effective Aug. 20, 2026
Kiora Pharmaceuticals enters an exclusive license agreement with CKD effective August 20, 2026, with CKD paying Kiora $1M up-front and eligible for double digit royalties on KIO-301 net sales in South Korea.
MNA | Aug 19, 2026, 11:02 AM UTC